Blockchain networks face a quiet but serious problem that grows over time. As transactions pile up, nodes must store more ...

Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

Recursion Pharmaceuticals (RXRX) posted another year of accelerating losses, with net losses growing at 35.2% per year over the last five years. Despite ongoing red ink, revenue is forecast to climb ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...

On Tuesday, Jefferies initiated coverage on Recursion Pharmaceuticals, a company trading on the NASDAQ under the ticker NASDAQ:RXRX, with a Hold rating on the stock. The firm also set a price target ...

They're both liable to grow by a lot, but one of them is a safer bet in the near term. However, both stocks have had a rough go of it lately, falling sharply over the past 12 months even as the ...